Orikine Bio — Seed · €5.5M

Orikine Bio, a synthetic-biology spin-off of Barcelona's Centre for Genomic Regulation developing engineered cytokines ('Foldikines') for autoimmune and inflammatory disease, closed a €5.5M Series Seed. The round was co-led by Sabadell Asabys and AdBio Partners with no single lead named, and will fund pre-clinical development of its lead candidates.